Metraipolis › archive › dc_7aedb85a13c2

Antibody-drug conjugates in breast cancer: redefining targeted therapy — Europe PMC PMID:42820303

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42820303
DOI
10.1172/jci207630
License (as archived)
solo-consultazione
Archived
2026-10-07T16:33:35.360Z
SHA-256 of the archived text
0f8058116f305e03791581d79543af88f6ffb38ee3d207b02937ce12ed175224
Stable URL of this page
https://metraipolis.com/documento/dc_7aedb85a13c2

How to cite

Antibody-drug conjugates in breast cancer: redefining targeted therapy — Europe PMC PMID:42820303 — Europe PMC (en), https://europepmc.org/article/MED/42820303 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7aedb85a13c2 (Metraipolis archive dc_7aedb85a13c2, sha256 0f8058116f305e03791581d79543af88f6ffb38ee3d207b02937ce12ed175224)
BibTeX
@misc{dc7aedb85a13c2,
  title = {Antibody-drug conjugates in breast cancer: redefining targeted therapy — Europe PMC PMID:42820303},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42820303},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7aedb85a13c2; sha256 0f8058116f305e03791581d79543af88f6ffb38ee3d207b02937ce12ed175224},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42820303. Agents can read the archived copy with the MCP tool read_document.